Parcopa vs Rytary (IPX066)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Parcopa
Rights held by UCB; US product discontinued
NCT00139867 · Phase 3 · completed
The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Onset of action: time to a 30% decrease in UPDRS Motor Exam (Part III) total score after identical doses of Parcopa and Sinemet: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)
Result source: NCT00139880
Rytary (IPX066)
Marketed by Amneal Pharmaceuticals
NCT00974974 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).
Reported efficacy
Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)
Result source: NCT00974974
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Parcopa | Rytary (IPX066) |
|---|---|---|
| OFF time, change | —Not posted · NCT00139880 | —Not reported |
| ON time without troublesome dyskinesia, change | —Not posted · NCT00139880 | —Not reported |
| UPDRS Part III, change | —Not posted · NCT00139880 | 21.6 vs 25.5vs IR CD-LDNCT00869791 |
| MDS-UPDRS Part II, change | —Not posted · NCT00139880 | —Not reported |
OFF time, change
- Parcopa
- —Not posted · NCT00139880
- Rytary (IPX066)
- —Not reported
ON time without troublesome dyskinesia, change
- Parcopa
- —Not posted · NCT00139880
- Rytary (IPX066)
- —Not reported
UPDRS Part III, change
- Parcopa
- —Not posted · NCT00139880
- Rytary (IPX066)
- 21.6 vs 25.5vs IR CD-LDNCT00869791
MDS-UPDRS Part II, change
- Parcopa
- —Not posted · NCT00139880
- Rytary (IPX066)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Parcopa: 2 of 4 rows · Rytary (IPX066): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Parcopa | Rytary (IPX066) |
|---|---|---|
| Dropout rate | —a NCT00590122 · Phase 4 · registry result, not featured evidence | —b NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results24.5%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 20.2%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 17.2%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 —Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence —Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence —Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence — NCT01130493 · Phase 3 · registry result, not featured evidence 8.1% NCT01096186 · Phase 3 · registry result, not featured evidence — NCT00869791 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00590122 · Phase 4 · registry result, not featured evidence | —b NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results15.3%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 14.4%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 5.7%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 —Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence —Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence —Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence — NCT01130493 · Phase 3 · registry result, not featured evidence 2.6% NCT01096186 · Phase 3 · registry result, not featured evidence — NCT00869791 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%a NCT00590122 · Phase 4 · registry result, not featured evidence | 5.5%b NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results2%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 4.8%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 4.6%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 2.3%Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence 15.6%Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence 25%Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence 1.1% NCT01130493 · Phase 3 · registry result, not featured evidence 7% NCT01096186 · Phase 3 · registry result, not featured evidence 0% NCT00869791 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 9 more results390 mg LD nausea 20.4% (placebo 8.7%) headache 17.3% (placebo 10.9%) dizziness 12.2% (placebo 5.4%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 245 mg LD dizziness 19.2% (placebo 5.4%) nausea 19.2% (placebo 8.7%) headache 12.5% (placebo 10.9%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 145 mg LD nausea 13.8% (placebo 8.7%) dizziness 9.2% (placebo 5.4%) headache 6.9% (placebo 10.9%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 upper respiratory infection 15.6% anxiety 6.3% fall 6.3% NCT01411137 · Phase 3 · registry result, not featured evidence fall 16.7% orthostatic hypotension 16.7% anxiety 8.3% NCT01411137 · Phase 3 · registry result, not featured evidence dyskinesia 4.5% confusional state 3.4% insomnia 3.4% NCT01130493 · Phase 3 · registry result, not featured evidence anxiety 3.7% fatigue 3.7% feeling of warth in abdomen 3.7% NCT00869791 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Parcopa
Rytary (IPX066)
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 3 more results
+ 4 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Parcopa's landscape · Rytary (IPX066)'s landscape